International Assets Investment Management LLC Purchases 320 Shares of Zoetis Inc. (NYSE:ZTS)

International Assets Investment Management LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 13.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,749 shares of the company’s stock after purchasing an additional 320 shares during the period. International Assets Investment Management LLC’s holdings in Zoetis were worth $459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Blue Bell Private Wealth Management LLC boosted its holdings in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the period. Independence Bank of Kentucky boosted its stake in shares of Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Private Wealth Management Group LLC bought a new position in shares of Zoetis in the fourth quarter worth about $33,000. Ramirez Asset Management Inc. purchased a new position in Zoetis in the 3rd quarter worth about $35,000. Finally, Gladius Capital Management LP bought a new stake in Zoetis during the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $171.83 on Tuesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The firm has a market cap of $78.41 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 2.66 and a beta of 0.89. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The firm has a 50-day simple moving average of $167.00 and a two-hundred day simple moving average of $179.11.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter in the prior year, the company posted $1.31 earnings per share. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, equities analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.01%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 33.33%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the sale, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. HSBC decreased their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. Barclays decreased their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Finally, The Goldman Sachs Group dropped their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.